Gene
ERCC4
ERCC4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (4), Actionable biomarkers (1), Trial mentions (10), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERCC4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 1 of 8,285 | 0.01% | 4 of 13,598 | 0.03% |
| 2021 | 2 of 8,692 | 0.02% | 6 of 15,045 | 0.04% |
| 2020 | 0 of 7,640 | 0.00% | 0 of 14,459 | 0.00% |
| 2019 | 0 of 7,300 | 0.00% | 4 of 12,159 | 0.03% |
| 2018 | 2 of 6,927 | 0.03% | 4 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 6 of 11,595 | 0.05% |
Showing 10 of 37 years.
Assay-provider ledger (4)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Affymetrix | Reagent supplier | Clinical validation | 1 | May 15, 2014 |
| Ingenuity Systems | Reagent supplier | Clinical validation | 2 | May 15, 2014 |
| Gene Express, Inc. | Unclassified | Clinical validation | 1 | November 15, 2009 |
| On-Q-ity, Inc. | Diagnostic provider | Analytical validation | 1 | Date unknown |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERCC4 oncogenic mutation | CISPLATIN | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
Trial mentions (10)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05986071 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT04912856 | Trial eligibility (AACT) |
| NCT05515575 | Trial eligibility (AACT) |
| NCT03448718 | Trial eligibility (AACT) |
Showing 5 of 10 trial mentions.
Target-disease associations (311)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxypyridine sulfate measurement | measurement | GWAS credible sets |
| Abnormality of blood and blood-forming tissues | phenotype | Variant curation (ClinVar / EVA) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Appendix Adenocarcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 311 associations.
Vendor sourcing (44)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The ERCC4 c.1622A>T; p.Asp541Val variant (rs2032270734), to our knowledge, is not reported in the medical literature or gene specific databases. This variant... | View ClinVar record SCV005877250.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1334A>C (p.K445T) alteration is located in exon 8 (coding exon 8) of the ERCC4 gene. This alteration results from a A to C substitution at nucleotide p... | View ClinVar record SCV003528405.2 |
| Astrazeneca Plc | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | #8) may have an ECOG Performance Status of ≤ 2. * Histological or cytological evidence/confirmation of urothelial cancer. * Metastatic and/or unresectable (c... | View trial NCT03448718 |
| Astrazeneca Plc | Trial collaborator | Mentioned in trial textTrial free-text mention | ERCC4 | View trial NCT03448718 |
| Baptist Health South Florida | Trial sponsor | Mentioned in trial textTrial free-text mention | XPF | View trial NCT01611454 |
Showing 5 of 44 sourcing records.
Trial-cited literature (44)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| <i>Amelogenesis imperfecta</i>: Next-generation sequencing sheds light on Witkop's classification. | Frontiers in physiology | 2023 | 51 |
| Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. | JCO precision oncology | 2023 | 27 |
| Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | 23 |
| The Effect of Final Irrigation Agitation Techniques on Postoperative Pain after Single Visit Root Canal Treatment of Symptomatic Irreversible Pulpitis: A Randomised Clinical Trial. | European endodontic journal | 2023 | 12 |
| Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. | Frontiers in pain research (Lausanne, Switzerland) | 2022 | 27 |
Showing 5 of 44 papers.
Protein variant mentions (56)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A109T | 1 | 2015 | PMID 25741868 |
| p.A235T | 1 | 2015 | PMID 25741868 |
| p.A808G | 1 | 2015 | PMID 25741868 |
| p.A860D | 1 | 2015 | PMID 25741868 |
| p.E368K | 1 | 2015 | PMID 25741868 |
Showing 5 of 56 variants.
Literature-extracted relations (8)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Ozone | Chemical | positive_correlate |
Effects of mild ozonisation on gene expression and nuclear domains organization in vitro. | 2017 |
| CISPLATIN | Chemical | associate |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. | 2013 |
| DNA Repair-Deficiency Disorders | Disease | associate |
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. | 2018 |
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. | 2013 |
| Adenocarcinoma of Lung | Disease | associate |
EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. | 2013 |
Showing 5 of 8 relation assertions.
Organizations publishing (66)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 3 | 2010 to 2023 |
| Duke University Health System | Academic | 2 | 2018 to 2023 |
| Mass General Brigham | Hospital | 2 | 2018 to 2023 |
| University of Verona | Academic | 2 | 2017 to 2019 |
| Université de Strasbourg | Academic | 2 | 2019 to 2023 |
Showing 5 of 66 organizations.
Where ERCC4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
272 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.